PNC Financial Services Group Inc. Sells 362 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

PNC Financial Services Group Inc. decreased its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 2.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 15,371 shares of the specialty pharmaceutical company’s stock after selling 362 shares during the quarter. PNC Financial Services Group Inc.’s holdings in Supernus Pharmaceuticals were worth $556,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of SUPN. Pacer Advisors Inc. lifted its position in Supernus Pharmaceuticals by 29.9% during the third quarter. Pacer Advisors Inc. now owns 1,752,882 shares of the specialty pharmaceutical company’s stock worth $54,655,000 after purchasing an additional 403,028 shares during the period. Raymond James Financial Inc. bought a new stake in Supernus Pharmaceuticals during the fourth quarter worth about $6,847,000. Connor Clark & Lunn Investment Management Ltd. lifted its position in Supernus Pharmaceuticals by 145.7% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 214,864 shares of the specialty pharmaceutical company’s stock worth $6,699,000 after purchasing an additional 127,420 shares during the period. Charles Schwab Investment Management Inc. lifted its position in Supernus Pharmaceuticals by 14.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 712,395 shares of the specialty pharmaceutical company’s stock worth $22,212,000 after purchasing an additional 91,354 shares during the period. Finally, Geode Capital Management LLC lifted its position in Supernus Pharmaceuticals by 5.3% during the third quarter. Geode Capital Management LLC now owns 1,482,051 shares of the specialty pharmaceutical company’s stock worth $46,218,000 after purchasing an additional 74,438 shares during the period.

Insider Activity

In other news, SVP Jonathan Rubin sold 927 shares of the company’s stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $39.15, for a total value of $36,292.05. Following the completion of the transaction, the senior vice president now owns 7,853 shares of the company’s stock, valued at $307,444.95. This represents a 10.56 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, VP Padmanabh P. Bhatt sold 9,477 shares of the stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $39.70, for a total value of $376,236.90. Following the completion of the transaction, the vice president now owns 10,149 shares in the company, valued at approximately $402,915.30. This represents a 48.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 11,104 shares of company stock valued at $440,263 over the last quarter. 9.30% of the stock is owned by company insiders.

Supernus Pharmaceuticals Trading Down 0.8 %

Shares of NASDAQ SUPN opened at $32.03 on Thursday. The company has a market cap of $1.79 billion, a price-to-earnings ratio of 29.93 and a beta of 0.83. Supernus Pharmaceuticals, Inc. has a 12 month low of $25.53 and a 12 month high of $40.28. The stock has a 50-day moving average price of $35.90 and a two-hundred day moving average price of $35.11.

Analyst Upgrades and Downgrades

SUPN has been the subject of several research analyst reports. StockNews.com raised Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Sunday. Cantor Fitzgerald reissued a “neutral” rating and set a $36.00 target price on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 26th.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.